多元线性回归分析脑钠肽的影响因素(2)
参见附件(12kb)。
参考文献
[1] LI Nan WANG Jian-an Division of Clinical Pharmacology and Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.10.1631/ jzus,2005: B0877.
[2] CHEN Huai-sheng, CHEN Yu-cheng, ZENG Zhi， BNP concentration reaction to heart function and treatment in chronic congestive heart failure Cardiological Department of West China Hospital W C J ·P S,2004,19(3):172～175,1006-0103(2004) 03-0172 - 04.
[3] Emily Lubien， Anthony DeMaria， Padma Krishnaswamy， et al. Circulation,2002,105:595-601.
[4] Obineche EN, Pathan JY, Fisher S, Prickett TC, Yandle TG, Frampton CM, Cameron VA, Nicholls MGNatriuretic peptide and adrenomedullin levels in chronic renal failure and effects of peritoneal dialysis.Kidney Int,2006,69(1):152-6.
[5] Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriureticpeptide concentrations in patients with end2stage renal disease: role ofbrain natriuretic peptide as a biomarker for ventricular remodeling.Mayo Clin Proc,2001, 76: 111121119.
[6] Mills RM, LeJemtel TH, Horton DP, Liang C, Lang R, Silver MA, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol，1999，34:155-162.
[7] Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med，2000，343:246-253.
参考文献
[1] LI Nan WANG Jian-an Division of Clinical Pharmacology and Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.10.1631/ jzus,2005: B0877.
[2] CHEN Huai-sheng, CHEN Yu-cheng, ZENG Zhi， BNP concentration reaction to heart function and treatment in chronic congestive heart failure Cardiological Department of West China Hospital W C J ·P S,2004,19(3):172～175,1006-0103(2004) 03-0172 - 04.
[3] Emily Lubien， Anthony DeMaria， Padma Krishnaswamy， et al. Circulation,2002,105:595-601.
[4] Obineche EN, Pathan JY, Fisher S, Prickett TC, Yandle TG, Frampton CM, Cameron VA, Nicholls MGNatriuretic peptide and adrenomedullin levels in chronic renal failure and effects of peritoneal dialysis.Kidney Int,2006,69(1):152-6.
[5] Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriureticpeptide concentrations in patients with end2stage renal disease: role ofbrain natriuretic peptide as a biomarker for ventricular remodeling.Mayo Clin Proc,2001, 76: 111121119.
[6] Mills RM, LeJemtel TH, Horton DP, Liang C, Lang R, Silver MA, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol，1999，34:155-162.
[7] Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med，2000，343:246-253.
您现在查看是摘要介绍页，详见PDF附件(12kb)。